Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Amgen Inc. (AMGN)

437.23 -6.89 (-1.55%)
At close: September 4 at 4:00:01 PM EDT
415.00 -22.23 (-5.08%)
After hours: September 4 at 7:59:10 PM EDT
Trade Amgen on Coinbase
Chart Range Bar
Loading chart for AMGN

What's happening with AMGN?

9m ago
Powered by Yahoo Scout

Amgen continues to show strong performance with recent positive clinical trial results for its drugs, particularly Repatha and MariTide, which could expand market opportunities. However, regulatory challenges for Tavneos and rising costs pose risks to its growth trajectory.

Powered by Yahoo Scout
  • Previous Close 444.12
  • Open 435.01
  • Bid 437.47 x 100
  • Ask 430.60 x 100
  • Day's Range 435.01 - 441.66
  • 52 Week Range 269.77 - 447.03
  • Volume 1,615,172
  • Avg. Volume 2,673,777
  • Market Cap (intraday) 236.381B
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) 27.55
  • EPS (TTM) 15.87
  • Earnings Date (est.) Nov 3, 2026
  • Forward Dividend & Yield 10.08 (2.27%)
  • Ex-Dividend Date Aug 21, 2026
  • 1y Target Est 389.69

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

www.amgen.com

31,500

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMGN
36.32%
S&P 500 (^GSPC)
12.75%

1-Year Return

AMGN
60.43%
S&P 500 (^GSPC)
18.71%

3-Year Return

AMGN
86.34%
S&P 500 (^GSPC)
70.93%

5-Year Return

AMGN
125.66%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 8.62B
Earnings 1.82B
Profit Margin 21.11%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
2B
4B
6B
8B
15.0%
20.0%
25.0%
30.0%

Analyst Insights

View More

Analyst Price Targets

230.00 Low
389.69 Average
437.23 Current
457.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/4/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Equal-Weight
Price Action Raises
Price Target 400 -> 435

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    22.95%

  • Return on Assets (ttm)

    8.67%

  • Return on Equity (ttm)

    91.47%

  • Revenue (ttm)

    38.09B

  • Net Income Avi to Common (ttm)

    8.74B

  • Diluted EPS (ttm)

    15.87

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.99B

  • Total Debt/Equity (mrq)

    490.28%

  • Levered Free Cash Flow (ttm)

    8.65B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: